ABILIFY MAINTENA KIT (aripiprazole) by Otsuka is unknown. Approved for schizophrenia, bipolar disorder. First approved in 2013.
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
ABILIFY MAINTENA KIT is an extended-release intramuscular suspension of aripiprazole, an atypical antipsychotic approved in 2013. It treats schizophrenia, bipolar disorder, schizoaffective disorder, major depressive disorder, autism spectrum disorder, Tourette's disorder, OCD, and other psychiatric and neurological conditions. The mechanism involves partial agonist activity at dopamine D2 and serotonin 5-HT1A receptors combined with antagonist activity at 5-HT2A receptors.
Peak lifecycle product with stable market position; brand teams typically maintain established commercial infrastructure focused on market defense rather than aggressive growth.
unknown. The efficacy of aripiprazole could be mediated through a combination of partial agonist activity at dopamine D 2 and serotonin 5-HT 1A receptors and antagonist activity at 5-HT 2A receptors.
A Double-Blind, Randomized Comparative Study of Carliprazine and Aripiprazole in Patients with Acute Schizophrenia
Aripiprazole Once-Monthly in Hospitalized Patients (INITIATE)
Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode
A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolar 1 Disorder
DIMES - DIgital MEdicine Study for Adults With Schizophrenia, Bipolar I Disorder, or Major Depression Currently Using Aripiprazole
Worked on ABILIFY MAINTENA KIT at Otsuka? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moABILIFY MAINTENA offers stable but non-growth career opportunities; the brand is in peak lifecycle with mature commercial infrastructure and limited expansion potential. Roles are primarily focused on market defense, compliance, and adherence initiatives rather than launch dynamics or clinical development.